Literature DB >> 25610724

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies.

Roch Houot1, Holbrook Kohrt2.   

Abstract

Some evidence suggests that monoclonal antibodies (mAb) can induce an adaptive immune response against tumor cells ("vaccinal effect"). Recently, we have shown that an anti-CD137 mAb can enhance the "vaccinal effect" of an anti-tumor mAb (cetuximab), thereby transforming a passive, monoclonal, short-term immunotherapy into an active, polyclonal, long-lasting immune response.

Entities:  

Keywords:  ADCC, antibody-dependent cellular cytotoxicity; Ag, antigens; CDC, complement-dependent cytotoxicity; CRC, colorectal cancer; DC, dendritic cells; FcR, Fc receptor; HN, head and neck; MHC, major histocompatibility complex; NK, natural killer; TCR, T cell receptor; antibody-dependent cell mediated cytotoxicity (ADCC); immunotherapy; mAb, monoclonal antibodies; monoclonal antibody; natural killer cells

Year:  2014        PMID： 25610724      PMCID： PMC4292240          DOI： 10.4161/21624011.2014.941740

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

Authors:  Nicole Selenko; Otto Majdic; Ulrich Jäger; Christian Sillaber; Johannes Stöckl; Walter Knapp
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

2.  Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.

Authors:  Riad Abès; Emmanuelle Gélizé; Wolf Herman Fridman; Jean-Luc Teillaud
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

3.  CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Kipp Weiskopf; Ash A Alizadeh; Josh Brody; Antonia Müller; Russell Pachynski; Debra Czerwinski; Steven Coutre; Mark P Chao; Lieping Chen; Thomas F Tedder; Ronald Levy
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

4.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Authors:  SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

Review 5.  Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Authors:  Louis M Weiner; Rishi Surana; Shangzi Wang
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

6.  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Authors:  Holbrook E Kohrt; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Ferenc Scheeren; Debra Czerwinski; A Dimitrios Colevas; Wen-Kai Weng; Michael F Clarke; Robert W Carlson; Frank E Stockdale; Joseph A Mollick; Lieping Chen; Ronald Levy
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

7.  Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Authors:  Raghvendra M Srivastava; Steve C Lee; Pedro A Andrade Filho; Christopher A Lord; Hyun-Bae Jie; H Carter Davidson; Andrés López-Albaitero; Sandra P Gibson; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

Review 8.  From the bench to the bedside: ways to improve rituximab efficacy.

Authors:  Guillaume Cartron; Hervé Watier; Josée Golay; Philippe Solal-Celigny
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

9.  Targeting CD137 enhances the efficacy of cetuximab.

Authors:  Holbrook E Kohrt; A Dimitrios Colevas; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Peder Lund; Antonia Mueller; Idit Sagiv-Barfi; Aurelien Marabelle; Ruth Lira; Emily Troutner; Lori Richards; Amanda Rajapaska; Jonathan Hebb; Cariad Chester; Erin Waller; Anton Ostashko; Wen-Kai Weng; Lieping Chen; Debra Czerwinski; Yang-Xin Fu; John Sunwoo; Ronald Levy
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

10.  Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.

Authors:  Shannon P Hilchey; Ollivier Hyrien; Tim R Mosmann; Alexandra M Livingstone; Jonathan W Friedberg; Faith Young; Richard I Fisher; Raymond J Kelleher; Richard B Bankert; Steven H Bernstein
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113
  10 in total
  6 in total

Review 1.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

2.  CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.

Authors:  Raghvendra M Srivastava; Sumita Trivedi; Fernando Concha-Benavente; Sandra P Gibson; Carly Reeder; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2016-08-05       Impact factor: 12.531

3.  CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.

Authors:  Lena M Kranz; Matthias Birtel; Christina Krienke; Christian Grunwitz; Jutta Petschenka; Kerstin C Reuter; Niels van de Roemer; Fulvia Vascotto; Mathias Vormehr; Sebastian Kreiter; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2015-07-17       Impact factor: 3.452

Review 4.  Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.

Authors:  Qing Ji; Qi Li; Jing Zhou
Journal:  J Exp Clin Cancer Res       Date:  2021-10-18

Review 5.  Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.

Authors:  Julie Jacobs; Evelien Smits; Filip Lardon; Patrick Pauwels; Vanessa Deschoolmeester
Journal:  J Immunol Res       Date:  2015-10-29       Impact factor: 4.818

Review 6.  Why are vaccines against many human viral diseases still unavailable; an historic perspective?

Authors:  Gregory A Tannock; Hyunsuh Kim; Lumin Xue
Journal:  J Med Virol       Date:  2019-10-03       Impact factor: 2.327
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.